A cross-over proof of concept study to investigate the intra-tumoral pharmacokinetics of CriPec® docetaxel versus Taxotere®
Latest Information Update: 01 Aug 2021
At a glance
- Drugs Docetaxel (Primary) ; Docetaxel (Primary)
- Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Urogenital cancer
- Focus First in man; Pharmacokinetics; Proof of concept
- Acronyms the CRITAX study
- 22 Apr 2020 Results published in the Clinical Cancer Research
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 17 May 2019 Results published in the Media Release